Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NSCLC × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Non-small Cell Lung Cancer Metastatic 1 NSCLC 1 Brain Neoplasms 1 Advanced Non-small Cell Lung Cancer 1

Interventions

osimertinib 3 Vinorelbine 3 Pemetrexed 3 Cisplatin 3 Carboplatin 3 Gemcitabine 2 Docetaxel 2 CP protocol 2 pembrolizumab 1 aumolertinib 1 Taxes 1 Paclitaxel 1 HMPL-013 1 HM781-36B 1 Gefitinib 1 Erlotinib Hydrochloride 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡